Treating KRAS-mutant NSCLC: latest evidence and clinical consequences

KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido, Pilar, Olmedo, María Eugenia, Gómez, Ana, Paz Ares, Luis, López-Ríos, Fernando, Rosa-Rosa, Juan Manuel, Palacios, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564881/
https://www.ncbi.nlm.nih.gov/pubmed/29081842
http://dx.doi.org/10.1177/1758834017719829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564881/
https://www.ncbi.nlm.nih.gov/pubmed/29081842
http://dx.doi.org/10.1177/1758834017719829

Ejemplares similares